Recruiting

Phase 2

TolaSure GelA Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

Sponsor:

BioMendics, LLC

Code:

NCT07027345

Conditions

Epidermolysis Bullosa Simplex

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Not accepted

Interventions

5% TolaSure Topical Gel

Topical Placebo Gel

Study Details

Brief summary:

This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (2 years of age and older) diagnosed with localized, intermediate, or severe epidermolysis bullosa simplex (EBS). Each patient (40 to complete) will be enrolled in the study and will be randomized to receive either TolaSure Gel or a topical Placebo for daily application for 2-months. After 2-months, all patients will receive TolaSure Gel to daily apply for an additional 2-months. A remote follow-up visit will occur 2-months after the end of study. Total time in the study is 6-months. Localized patients will be applying study medication to their feet, with the option to treat their hands as well throughout the study. Intermediate and severe EBS patients will be applying study medication to randomized treatment area(s) (a minimum of \~2-3% Body Surface Area (BSA)), with the option to treat their feet as well throughout the study.

Conditions

Epidermolysis Bullosa Simplex

Study ID

NCT07027345

Start date

Sep 11, 2025

Status verified date

Aug, 2026

Completion date

Sep, 2027

Anticipated

Primary completion date

Jan, 2027

Anticipated

Eligibility Criteria

Sex: All

Age: 2+

Healthy Volunteers: Not accepted

Inclusion Criteria:

Patient is a male or female at least 2 years of age.
Patient has a documented diagnosis and confirmed clinical history of localized (previously known as Weber-Cockayne), intermediate (previously Kӧbner), or severe (previously EBS-Dowling Meara) autosomal dominant EBS and/or a genetic mutation in either the KRT14 or KRT5 gene consistent with localized, intermediate, or severe EBS. The Investigator will determine patient eligibility based on historical phenotypic presentation of EBS symptoms along with genetic/diagnosis documentation to determine EBS severity. (If localized, intermediate, or severe EBS is suspected but not diagnosed or genetically confirmed, confirmatory testing will be performed).
For localized EBS participants:

Patient must have at least moderate plantar disease activity, defined as ≥15% involvement of the plantar surface of at least one foot, as assessed by clinical examination or standardized imaging, with evidence of active disease (e.g., blisters, erosions, or crusting).
For treatment, the Target Lesional Area (TLA) will consist of daily treating the feet (tops and bottoms) which is approximately 7% body surface area (BSA). Localized EBS subjects will also have the option to treat their hands (tops and bottoms), which is approximately an additional 6% BSA. Palmoplantar evaluation is separate from the intermediate to severe TLA-treated regions per protocol.
For intermediate to severe EBS participants: Patient is actively flaring in one of the preferred target lesional areas (TLAs): 1) lower extremities (ideally below the knee and above the ankle or between the knee and top of the thigh) or 2) torso (excluding the groin and apocrine areas). The following skin conditions are required for treatment purposes:

A TLA is defined as a contiguous or non-contiguous region totaling up to \~15-20% body surface area (BSA).
A flare is defined as a minimum area of \~2-3% Body Surface Area (BSA) containing intact blisters (of varying size and number), and freshly ruptured blisters across 50% of the TLA (as assessed by the principal investigator (PI)). Skin erosions, keratoderma, fissures and/or erythema may also be present.
Patients will be permitted to treat their feet to assess plantar blister surface area but blistering on the feet is not a requirement for study inclusion and is evaluated separately per protocol.
For all patients (with localized, intermediate, and severe EBS), the TLA may not be infected (as assessed by PI) or have been treated with a topical antibiotic within 14 days.
If the patient is a woman of childbearing potential (WOCBP),

Has a negative urine pregnancy test.
Agrees to use an approved effective form of birth control with failure rates <1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomized partner) during participation in the study (and at least 3 months thereafter).
Is not nursing.
Patient's laboratory values (blood and urine) are within the range of normal or abnormal values are within normal levels for the disease and in the opinion of the PI the values are not clinically relevant for study participation.
Patient is in good, general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of the EBS lesions or which exposes the subject to an unacceptable risk by study participation.
Over the duration of the study, the patient agrees to not use any other topical therapies and/or impregnated dressings within the TLAs (e.g., medicated cleansers, CBD oil, MediHoney, Silvadine cream 1%, topicals containing antimicrobials, keratin, and/or collagen, lipido-colloid or polymeric membrane dressings, and/or hydrogels).
Patient and/or legally appointed and authorized representative must be able and willing to follow study procedures and instructions in order to maintain compliance throughout the study period.
The patient or legally appointed and authorized representative must have read, understood and signed an Institutional Review Board/Ethics Committee (IRB/EC) approved Informed Consent or Assent Form.

Exclusion Criteria:

Patient's use of prior or concomitant medication or medical treatments/procedures:

Any investigational drug or therapy within 30 days.
Systemic steroidal therapy within 30 days.
Topical steroidal therapy within 14 days (Note: inhaled and ophthalmic products containing steroids are allowed).
Systemic antibiotic therapy within 7 days.
Currently receiving chemotherapy or radiation.
Surgery within the previous 2 weeks (except for minor surgery, cosmetic or dental procedures as determined by the investigator).
Started to take chronic medications (NSAIDs, antihistamines, etc.) at least 30 days prior to starting study medication.
Patient's medical history includes:

Cancer that is currently undergoing treatment.
History of chronic and severe vitamin, mineral, or protein deficiency.
Current systemic infection.
HIV/AIDS.
Non-EBS skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn) that, in the opinion of the investigator, might put the patient at undue risk by study participation or interferes with the study medication application or the study assessments.
An illness (e.g., neurological, cardiovascular, respiratory, hepatic, renal, or metabolic disease), condition, or situation that in the opinion of the principal investigator is likely to interfere with the patient's participation in or completion of the study.
Factors present in the patient and/or his/her legal representative that could interfere with study compliance such as inability to attend scheduled study visits or to perform study protocol procedures.
Patient is a member of the investigational team or his/her immediate family.
Other unspecified reasons that, in the opinion of the Investigator, make the patient unsuitable for enrollment.

Study Design

Enrollment

40 participants

Anticipated

Allocation

Randomized

Intervention Model

Crossover

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

active comparator: 5% TolaSure Topical Gel

5% (w/w) TolaSure Gel

placebo comparator: Topical Placebo Gel

Placebo Control Gel

Interventions

5% TolaSure Topical Gel

TolaSure Topical Gel is applied once-daily to designated treatment areas for up to 4 months (Part 2 End of Study).

Topical Placebo Gel

Topical Placebo Gel is applied once-daily to designated treatment areas for up to 2 months (Part 1 End of Study).

Primary outcome measure

Change in Blister Surface Area of the Designated Treatment Area(s) [ Time Frame: Day 1 (Baseline) and weekly until End of Study (2-months and maximum 4-months) ]

Central Contacts and Locations

Locations

Stanford University School of Medicine, Dermatology Department

Recruiting

Palo Alto, California, United States, 94304

Contacts

Thomas Buschbacher

650-313-0354 tbusch@stanford.edu

NU Dermatolgy CTU

Recruiting

Chicago, Illinois, United States, 60611

Contacts

NU Dermatolgy CTU

312-227-6817 NUderm-research@northwestern.edu

More Information

Sponsor

BioMendics, LLC

Last update posted

Aug 13, 2026

Last verified

Aug, 2026

Keywords

Epidermolysis Bullosa
Epidermolysis Bullosa Simplex
EBS
Severe EBS
EBS Dowling-Meara
EBS Koebner
Skin Diseases
Keratin
Aggregate
Mutant
EBS-DM
Keratin Disorder
Skin Abnormalities
generalized
intermediate

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by BioMendics, LLC on 2026-08-13.